Mycoplasma Testing Market: Market Size & Forecast 2026

Mycoplasma testing refers to diagnostic procedures used to detect mycoplasma species, a class of bacteria that lack cell walls, in cell cultures, biological reagents, and manufacturing environments. These microorganisms are among the most common and persistent contaminants in cell-based research and bioproduction, as they are undetectable by standard visual inspection yet can profoundly alter cellular metabolism, gene expression, and product quality. The market encompasses testing kits, instruments, reagents, and contract testing services across multiple methodologies including PCR, enzymatic assays, and culture-based techniques.

• •Global market valued at approximately $0.9 billion in 2025 with projections extending into the multi-billion dollar range by the early 2030s
• •Primary end-users include biopharmaceutical companies, contract manufacturing organizations, academic research institutions, and clinical laboratories
• •Testing is mandated or strongly recommended by major regulatory bodies including the FDA, EMA, and ICH guidelines for cell-based drug and vaccine manufacturing

The explosive growth of cell and gene therapies is perhaps the most significant market driver, as advanced therapy medicinal products require rigorous cell culture quality monitoring throughout their entire development and manufacturing lifecycle. Additionally, the global expansion of biopharmaceutical manufacturing capacity, particularly in emerging markets, creates sustained demand for contamination detection solutions. Growing scientific awareness of mycoplasma's impact on research reproducibility and drug development has led to stricter institutional and regulatory quality standards.

• •Cell-based therapies, CAR-T treatments, and mRNA vaccine platforms all require cell culture intermediates that must be regularly screened for mycoplasma contamination
• •Regulatory agencies increasingly enforce comprehensive quality testing for biologics and cell-based products, creating mandatory demand for reliable detection methods
• •Rising R&D spending in the biotechnology sector, coupled with the outsourcing of manufacturing to CMOs, expands the addressable market across geographies

The market is typically segmented by product type, including Kits and Assay Reagents, Instruments, and Contract Testing Services, and by testing method, such as PCR-based, DNA staining, enzymatic, and culture-based approaches. North America commands the largest market share due to its mature biotechnology ecosystem, stringent regulatory environment, and high concentration of major pharmaceutical companies. The Asia-Pacific region is experiencing the fastest growth, fueled by rapid expansion of biopharma manufacturing in China, India, and South Korea, as well as growing academic research investment.

• •PCR-based methods dominate the testing method segment due to their sensitivity, speed, and ability to detect a wide range of mycoplasma species simultaneously
• •North America holds approximately 40-45% of global market share, with strong contributions from the United States and Canada
• •Europe is the second-largest regional market, while Asia-Pacific is projected to achieve the highest compound growth rate through the decade

What are the recent trends and outlook?

The market is trending toward faster, more sensitive, and more comprehensive testing solutions, with PCR-based and next-generation sequencing methods gaining share over traditional culture-dependent approaches. Digitalization and automation in biopharmaceutical manufacturing are driving demand for integrated, high-throughput testing platforms that can deliver real-time results with reduced hands-on time. As the cell and gene therapy sectors mature and new biologics pipelines expand, mycoplasma testing is expected to become an even more deeply embedded component of the biomanufacturing quality control ecosystem.

• •Emerging technologies including digital PCR, loop-mediated isothermal amplification (LAMP), and NGS-based approaches are expanding detection capabilities and reducing time-to-result
• •The rise of single-use bioreactors and closed manufacturing systems is reducing contamination risk but simultaneously creating demand for inline and at-line monitoring technologies
• •Market consolidation through mergers and acquisitions is expected as larger life-science companies seek to expand their cell culture quality control product offerings